Sanofi S.A., FR0000120578

Sanofi stock at EUR 72.17 with volume 88.6 percent below average

Published on 10/12/2026 at 14:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jefferies kept a Buy rating and EUR 100 target on October 7, 2026. Sanofi stock traded at EUR 72.17 on October 12, 2026.

Key points in brief

Sanofi stock was at EUR 72.17 at Lang & Schwarz on October 12, 2026.
Trading volume was 226,870 shares, 88.6 percent below the 1,987,100-share average.
Jefferies maintained a Buy rating and EUR 100 target on October 7, 2026.
Sanofi had a EUR 86.6 billion market capitalization and a 22.27 P/E ratio.

Overhead flatlay of pharmaceutical objects on white surface including clear glass vials, a syringe, petri dish, test tubes, a pipette, and blue nitrile gloves — Sanofi FR0000120578 overhead flatlay of pharmaceutical vials, syringe, pipette, petri dish, and protective gloves, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) was trading at EUR 72.17 at Lang & Schwarz on October 12, 2026 at 2:40 p.m. CEST. Volume stood at 226,870 shares, 88.6 percent below the 1,987,100-share average, putting liquidity ahead of the latest price move in this market report. According to Markets Insider on October 7, 2026, Jefferies maintained a Buy rating and a EUR 100.00 price target for Sanofi.

Volume stays below average

The current EUR 72.17 quote sits inside Sanofi's EUR 69.75 to EUR 91.15 52-week range as of October 12, 2026. The price is 20.82 percent below the range high, while the 52-week low is EUR 69.75.

Sanofi's market capitalization was EUR 86.6 billion on October 12, 2026. Its P/E ratio was 22.27 and its trailing dividend yield was 0.12 percent, giving the price report a valuation frame without relying on a corporate announcement.

Valuation versus drugmakers

Jefferies' EUR 100.00 target lies 38.56 percent above the EUR 72.17 Lang & Schwarz price. The target and the Buy rating were attributed to analyst Michael Leuchten in the October 7, 2026 report by Markets Insider.

Comparison with peers

Sanofi: , P/E 22.27, market capitalization EUR 86.6 billion

GSK (LSE, GBp): plus 0.49 percent, P/E 14.80, market capitalization GBP 70.5 billion

AstraZeneca (LSE, GBp): plus 0.47 percent, P/E 23.88, market capitalization GBP 186.9 billion

Results date is October 30

Sanofi's next scheduled reporting event is the third-quarter 2026 results release on October 30, 2026. The company confirmed that date in its October 6, 2026 release, which also said the aide-mémoire for the quarter had been posted on the investor-relations site, according to Sanofi.

The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.